Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Variant PNLDC1, Defective piRNA Processing, and Azoospermia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vitamin E and acute graft-versus-host disease after myeloablative allogeneic hematopoietic cell transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Treatment of monogenic disorders with viral transduced haematopoietic stem cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Robert Zeiser
  • Nikolas von Bubnoff
  • Jason Butler
  • Mohamad Mohty
  • Dietger Niederwieser
  • Reuven Or
  • Jeff Szer
  • Eva M Wagner
  • Tsila Zuckerman
  • Bruyère Mahuzier
  • Judith Xu
  • Celine Wilke
  • Kunal K Gandhi
  • Gérard Socié
  • REACH2 Trial Group
  • Brian Kornblit (Member of study group)
View graph of relations

BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD.

METHODS: We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56.

RESULTS: A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]).

CONCLUSIONS: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy. (Funded by Novartis; REACH2 ClinicalTrials.gov number, NCT02913261.).

Original languageEnglish
JournalThe New England journal of medicine
Volume382
Issue number19
Pages (from-to)1800-1810
Number of pages11
ISSN0028-4793
DOIs
Publication statusPublished - 7 May 2020

    Research areas

  • Acute Disease, Adolescent, Adult, Aged, Child, Female, Glucocorticoids/therapeutic use, Graft vs Host Disease/drug therapy, Humans, Janus Kinase Inhibitors/adverse effects, Male, Middle Aged, Pyrazoles/adverse effects, Stem Cell Transplantation/adverse effects, Thrombocytopenia/chemically induced, Transplantation, Homologous, Young Adult

ID: 61676534